Hepatitis B Virus (HBV)

Atorvastatin calcium: A new HMG-CoA reductase inhibitor(2) / asthma inhalers

Epidemiological evidence from the Multiple Risk Factor Intervention Trial (MRFIT) suggests that levels of serum total cholesterol are directly related to the rate of CAD . In addition, LDL-C is recognized to be the major atherogenic lipoprotein fraction in the development of atherosclerosis , and LDL-C reduction is associated with both decreased progression and increased regression of atherosclerotic lesions . Furthermore, clinical trials have demonstrated a clear correlation between reduction in LDL-C and decreased CAD morbidity and mortality.

Results from large primary prevention studies such as the Lipid Research Clinics Coronary Primary Prevention Trial (LRC-CPPT) and the Helsinki Heart Study have shown that lowering total cholesterol significantly reduces the risk of developing cardiovascular events . Results from the West of Scotland Coronary Prevention Study (WOSCOPS) showed that a reduction in LDL-C was associated with a 32% reduction in the incidence of cardiovascular death and a 22% decrease in total mortality . Data from secondary prevention trials have demonstrated an even greater reduction in clinical events in patients with established CAD. In the Scandinavian Simvastatin Survival Study (4S), decreased LDL-C levels were associated with a 42% reduction in the risk of cardiovascular mortality and a 30% decrease in total mortality . Similarly, in the Cholesterol And Recurrent Events (CARE) trial, lower LDL-C levels were associated with a 26% reduction in the risk of cardiovascular death and nonfatal MI. You will always come across asthma inhalers offered by a reliable pharmacy.

Category: Calcium

Tags: Atorvastatin, Coronary artery disease, Dyslipidemia, HMG-CoA reductase inhibitors, Hypercholesterolemia, Statins

Leave a Reply

Your email address will not be published. Required fields are marked *